Transfusion Independency and Histological Remission in a Patient with Advanced Primary Myelofibrosis Receiving Iron-Chelation Therapy with Deferasirox Oncol Res Treat 2016;39:384-387 - DOI:10.1159/000446029 © 2016 S. Karger AG, Basel
Transfusion Independency and Histological Remission in a Patient with Advanced Primary Myelofibrosis Receiving Iron-Chelation Therapy with Deferasirox Oncol Res Treat 2016;39:384-387 - DOI:10.1159/000446029 © 2016 S. Karger AG, Basel
Transfusion Independency and Histological Remission in a Patient with Advanced Primary Myelofibrosis Receiving Iron-Chelation Therapy with Deferasirox Oncol Res Treat 2016;39:384-387 - DOI:10.1159/000446029 Fig. 1. Hematoxylin and eosin (HE) staining, advanced stage of primary myelofibrosis with osteosclerosis, fibrosis and hypoplasia of hematopoietic cells, February 2014. 40× magnification. © 2016 S. Karger AG, Basel
Transfusion Independency and Histological Remission in a Patient with Advanced Primary Myelofibrosis Receiving Iron-Chelation Therapy with Deferasirox Oncol Res Treat 2016;39:384-387 - DOI:10.1159/000446029 Fig. 2. Serial blood results from February 2014 to October 2015 demonstrating improved hematopoiesis. Arrows mark start and stop of deferasirox. An arithmetic average of the first 3 values of each graph without units was determined and each lab result was divided with that average for statistical presentation of all lab results in 1 figure. This allowed a better visualization of trends in each graph. Therefore, the start point of all graphs is approximately 1; for example, platelets nearly quadrupled during treatment. © 2016 S. Karger AG, Basel
Transfusion Independency and Histological Remission in a Patient with Advanced Primary Myelofibrosis Receiving Iron-Chelation Therapy with Deferasirox Oncol Res Treat 2016;39:384-387 - DOI:10.1159/000446029 Fig. 3. HE staining, increased hematopoiesis with small and dysplastic megakaryocytes without fibrosis or osteosclerosis, May 2015. 40× magnification. © 2016 S. Karger AG, Basel